Citi has reiterated the Buy Rating on Watson Pharmaceuticals, Inc. WPI.
According to Citi, "Conclusion–WPI received final approval & shipped famciclovir, a generic version of NVS' Famvir, an oral antiviral used to treat herpes. This immediately followed expiration of pediatric exclusivity for Famvir's ‘937 patent on 3/21/11… We Reiterate Our Buy Rating & Maintain Our $67 Price Target, which assumes WPI trades at ~13x our 2012E EPS of $5.08, which is below WPI's 10-year historical median (22x) & average (23x) forward P/E multiple."
WPI has a $67.00 Price Target and shold for $55.12 a share yesterday at closing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in